No­var­tis pairs up with Cure­Vac to help dri­ve Covid-19 shot pro­duc­tion but may miss the show in the US, EU

With the pan­dem­ic po­ten­tial­ly en­ter­ing its lat­er stages, ma­jor drug­mak­ers like Mer­ck have jumped in to aid in the gar­gan­tu­an task of man­u­fac­tur­ing oth­er com­pa­nies’ vac­cines. Now, af­ter a rel­a­tive­ly qui­et year, No­var­tis is team­ing up with one of the mR­NA play­ers to help the pro­duc­tion crunch.

No­var­tis will help man­u­fac­ture bulk drug sub­stance for Cure­Vac’s mR­NA-based Covid-19 shot, dubbed CVn­CoV, at its Kundl, Aus­tria site with plans to pro­duce up to 50 mil­lion dos­es by the end of 2021, the Swiss drug­mak­er said Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.